These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 30471682)

  • 1. The renaissance in psychedelic research: What do preclinical models have to offer.
    Murnane KS
    Prog Brain Res; 2018; 242():25-67. PubMed ID: 30471682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders.
    Vollenweider FX; Kometer M
    Nat Rev Neurosci; 2010 Sep; 11(9):642-51. PubMed ID: 20717121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans.
    Heal DJ; Gosden J; Smith SL
    Neuropharmacology; 2018 Nov; 142():89-115. PubMed ID: 29427652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychedelic Drugs in Biomedicine.
    Kyzar EJ; Nichols CD; Gainetdinov RR; Nichols DE; Kalueff AV
    Trends Pharmacol Sci; 2017 Nov; 38(11):992-1005. PubMed ID: 28947075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating Addiction: Perspectives from EEG and Imaging Studies on Psychedelics.
    Tófoli LF; de Araujo DB
    Int Rev Neurobiol; 2016; 129():157-85. PubMed ID: 27503452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychedelics: Where we are now, why we got here, what we must do.
    Belouin SJ; Henningfield JE
    Neuropharmacology; 2018 Nov; 142():7-19. PubMed ID: 29476779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An introduction to psychedelic neuroscience.
    Calvey T; Howells FM
    Prog Brain Res; 2018; 242():1-23. PubMed ID: 30471677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychedelics and Personality.
    Aixalà M; Dos Santos RG; Hallak JEC; Bouso JC
    ACS Chem Neurosci; 2018 Oct; 9(10):2304-2306. PubMed ID: 29863323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders.
    Mertens LJ; Preller KH
    Pharmacopsychiatry; 2021 Jul; 54(4):176-190. PubMed ID: 33472250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Embedding existential psychology within psychedelic science: reduced death anxiety as a mediator of the therapeutic effects of psychedelics.
    Moreton SG; Szalla L; Menzies RE; Arena AF
    Psychopharmacology (Berl); 2020 Jan; 237(1):21-32. PubMed ID: 31784805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics.
    Jaster AM; González-Maeso J
    Mol Psychiatry; 2023 Sep; 28(9):3595-3612. PubMed ID: 37759040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Psychedelic Renaissance and Its Forensic Implications.
    Holoyda B
    J Am Acad Psychiatry Law; 2020 Mar; 48(1):87-97. PubMed ID: 31948993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Applications of Classic Hallucinogens.
    Bogenschutz MP; Ross S
    Curr Top Behav Neurosci; 2018; 36():361-391. PubMed ID: 28512684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review.
    DiVito AJ; Leger RF
    Mol Biol Rep; 2020 Dec; 47(12):9791-9799. PubMed ID: 33231817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers.
    Erritzoe D; Smith J; Fisher PM; Carhart-Harris R; Frokjaer VG; Knudsen GM
    J Psychopharmacol; 2019 Sep; 33(9):1068-1075. PubMed ID: 30816797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
    Majić T; Schmidt TT; Gallinat J
    J Psychopharmacol; 2015 Mar; 29(3):241-53. PubMed ID: 25670401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses.
    Chi T; Gold JA
    J Neurol Sci; 2020 Apr; 411():116715. PubMed ID: 32044687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychedelics and Neural Plasticity: Therapeutic Implications.
    Grieco SF; Castrén E; Knudsen GM; Kwan AC; Olson DE; Zuo Y; Holmes TC; Xu X
    J Neurosci; 2022 Nov; 42(45):8439-8449. PubMed ID: 36351821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular targets of psychedelic-induced plasticity.
    Jaster AM; de la Fuente Revenga M; González-Maeso J
    J Neurochem; 2022 Jul; 162(1):80-88. PubMed ID: 34741320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.